About ibio - IBIO
iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. It focuses on decreasing drug failures, shortening drug development timelines and opening up new frontiers against the most promising targets. The company was founded on April 17, 2008 and is headquartered in San Diego, CA.
IBIO At a Glance
iBio, Inc.
11750 Sorrento Valley Road
San Diego, California 92121
| Phone | 1-979-446-0027 | Revenue | 225.00K | |
| Industry | Pharmaceuticals: Other | Net Income | -24,907,000.00 | |
| Sector | Health Technology | Employees | 19 | |
| Fiscal Year-end | 06 / 2025 | |||
| View SEC Filings |
IBIO Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 35.926 |
| Price to Book Ratio | 0.853 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.108 |
| Enterprise Value to Sales | -7.407 |
| Total Debt to Enterprise Value | -2.676 |
IBIO Efficiency
| Revenue/Employee | 11,842.105 |
| Income Per Employee | -1,310,894.737 |
| Receivables Turnover | 0.316 |
| Total Asset Turnover | 0.006 |
IBIO Liquidity
| Current Ratio | 4.081 |
| Quick Ratio | 4.081 |
| Cash Ratio | 3.701 |
IBIO Profitability
| Gross Margin | -455.556 |
| Operating Margin | -7,392.889 |
| Pretax Margin | -6,863.556 |
| Net Margin | -11,069.778 |
| Return on Assets | -44.16 |
| Return on Equity | -84.147 |
| Return on Total Capital | -59.894 |
| Return on Invested Capital | -70.697 |
IBIO Capital Structure
| Total Debt to Total Equity | 20.915 |
| Total Debt to Total Capital | 17.298 |
| Total Debt to Total Assets | 15.522 |
| Long-Term Debt to Equity | 16.446 |
| Long-Term Debt to Total Capital | 13.601 |